We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Reliance Gen. | LSE:GMX | London | Ordinary Share | GB00B1MM9925 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.55 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:2576M GeneMedix PLC 12 June 2003 GENEMEDIX PLC Placing of new shares for cash GeneMedix plc ("GeneMedix" or "the Company"), the UK multi-sourced biopharmaceutical company with operations in Europe and Asia and with joint London and Singapore Stock Exchange listings, announces that, in response to investor demand it is raising approximately #1.5 million before expenses through a placing for cash of 8,983,003 new ordinary shares. The new shares, which represent approximately 3 per cent. of GeneMedix's issued share capital prior to the placing, have been placed with a number of investors in Singapore and Malaysia at a placing price of 16.65 pence per share. The placing price represents a discount of approximately 10 per cent. to the closing middle market price on London Stock Exchange on 11 June 2003. Paul Edwards, Chief Executive Officer, commented: "As we announced today in a separate press release, we have signed a letter of intent to establish a new company in Malaysia to develop and commercialise our insulin know-how. As part of this venture, local investors in Malaysia and Singapore were contacted to secure equity financing for the new company. Some of these investors expressed an interest in investing directly in GeneMedix and this placing provides them with the opportunity to secure a valuable shareholding in GeneMedix. The new shares will, when issued and fully paid, rank pari passu with the existing issued GeneMedix shares. Application will be made today to the UK Listing Authority for the new shares to be admitted to the Official List. Application will also be made to the London Stock Exchange for the new shares to be admitted to trading on its market for listing securities. It is expected that admission to listing of such securities will become effective and dealings on the London Stock Exchange will commence on 24 June 2003 and shortly thereafter in Singapore. 12 June 2003 ENQUIRIES: GeneMedix plc Tel: 01638 663 320 Paul Edwards, Chief Executive Officer College Hill Tel: 020 7457 2020 Nicholas Nelson Clare Warren This information is provided by RNS The company news service from the London Stock Exchange END IOEFTMJTMMMBBRJ
1 Year Reliance Genemedix Chart |
1 Month Reliance Genemedix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions